<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940803-2-00048</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>National Institutes of Health</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 -->  <DOCTITLE>Prospective Grant of Exclusive License: Recombinant Virus Expressing Human Carcinoembryonic Antigen and Methods of Use Thereof </DOCTITLE> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  National Institutes of Health, Public Health Service, DHHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Notice.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive license in the United States to practice the invention embodied in U.S. Patent Applications Numbers 07/695,024 filed on May 6, 1991 and 07/879,649 filed on May 6, 1992 entitled ``Recombinant Virus Expressing Human Carcinoembryonic Antigen and Methods of Use Thereof'', to Therion Biologics Corporation, having a place of business in Cambridge, MA. The patent rights in these inventions have been assigned to the United States of America.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the licenses would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.  <!-- PJG 0012 frnewline --> The field of use would be limited to the use of recombinant vaccinia and/or swinepox viruses expressing carcinoembryonic antigen (CEA) gene or portions thereof with the aim of eliciting an immunogenic response.  <!-- PJG 0012 frnewline --> The immune response  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vivo,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> elicited after exposure to the recombinant virus would be directed against malignant cells expressing CEA. The purpose of the license is to develop vaccinia and/or swine pox virus based vaccines directed against cancers expressing CEA.  <!-- PJG 0012 frnewline --> Requests for a copy of these patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Daniel R. Passeri, Office of Technology Transfer, National Institutes of Health, Box OTT, Bethesda, MD 20892. Telephone: (301)-496&hyph;7735, ext. 244; Facsimile: (301) 402&hyph;0220. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer within sixty (60) days of this notice will be considered. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: July 22, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUMMARY> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Barbara M. McGarey, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Deputy Director, Office of Technology Transfer.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;18826 Filed 8&hyph;2&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;P <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            